Cosmos Health Inc. announced a third consecutive purchase order for 60,000 units of its Sky Premium Life nutraceutical line from Pharmalink, the UAE’s largest healthcare distributor. The new order brings the cumulative total of Sky Premium Life units under the exclusive distribution agreement to 270,000 units, a figure that reflects the company’s steady growth in the Gulf market since the partnership began in June 2024.
The partnership was launched with an initial 130,000‑unit order in June 2024, followed by an 80,000‑unit order in May 2025. The latest 60,000‑unit order demonstrates that Pharmalink continues to place repeat orders, indicating sustained demand for Cosmos Health’s products in the region. The cumulative 270,000 units represent roughly 9 % of the company’s five‑year target of 3 million units, a milestone that could significantly increase the nutraceutical segment’s contribution to overall revenue.
Cosmos Health’s broader financial performance has shown improvement in recent quarters. In Q1 2025 the company reported a net loss of $818,097, a marked improvement from the $1,866,690 loss in Q1 2024. Full‑year 2024 revenue reached $54.43 million, up 2.0 % from the prior year. Gross margin in Q1 2025 expanded to 14.95 %, reflecting a shift toward higher‑margin products and operational efficiencies. The company projects a 75 % gross margin for its U.S. operations, underscoring the profitability potential of its high‑margin product lines.
Demand for Sky Premium Life in the UAE appears to be driven by a combination of factors, including targeted marketing campaigns, perceived product efficacy, competitive pricing, and expansion into new distribution channels. While the fact‑check report does not provide granular data on each driver, the consistent repeat orders from Pharmalink suggest that the product mix and pricing strategy are resonating with consumers in affluent markets such as Dubai and Abu Dhabi.
Management has highlighted the strategic importance of the Pharmalink partnership. CEO Greg Siokas said, “We are thrilled to announce our agreement with Pharmalink. This partnership will enable us to launch our Sky Premium Life products dynamically in the UAE, especially in affluent markets such as Dubai and Abu Dhabi. We project receiving purchase orders exceeding 3 million units over the next five years and look forward to expanding our collaboration with Pharmalink.” The quote underscores the company’s confidence in the partnership’s long‑term growth potential.
The third order not only brings Cosmos Health closer to its 3 million‑unit goal but also reinforces its position in the rapidly expanding GCC nutraceutical market, which was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033. By securing repeat orders from a major distributor, Cosmos Health is strengthening its supply chain, improving inventory turnover, and positioning itself to capture a larger share of the high‑margin segment. The cumulative 270,000 units represent a tangible step toward the company’s strategic expansion into the Gulf region and a potential boost to its overall revenue trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.